IP Library Granted Patent US 8,470,862
Granted Patent B2
US 8,470,862 · App. 13/096,387 · Granted Jun 25, 2013

Treatment or prevention of hypotension and shock

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,470,862
App. No.
13/096,387
Granted
Jun 25, 2013
Kind
B2
Abstract

A method for the prevention and treatment of hypotension and shock due to low peripheral resistance, comprising administering to a mammal in need thereof an effective amount of a certain imidazole derivative or pharmaceutically acceptable ester or salt thereof, and a method for the treatment of cardiopulmonary resuscitation, comprising administering to a mammal in need thereof an effective amount of a certain imidazole derivative or pharmaceutically acceptable ester or salt thereof.

Claims (14)

1. A method for the treatment of hypotension and shock due to low peripheral resistance, comprising administering to a mammal in need thereof an effective amount of an imidazole derivative of formula I:

wherein R is hydrogen or methyl, or a pharmaceutically acceptable ester or salt thereof.

2. The method according to claim 1 , wherein 3-(1H-imidazol-4-ylmethyl)-indan-5-ol is administered.

3. The method according to claim 2 , wherein 3-(1H-imidazol-4-ylmethyl)-indan-5-ol hydrochloride is administered.

4. The method according to claim 1 , wherein the administration is intravenous.

5. The method according to claim 1 , wherein the mammal is a human.

6. The method according to claim 4 , wherein the effective amount administered is about 10-500 μg/patient.

7. The method according to claim 6 , wherein the effective amount administered is about 30-200 μg/patient.

8. The method according to claim 2 , wherein the administration is intravenous.

9. The method according to claim 3 , wherein the administration is intravenous.

10. The method according to claim 2 , wherein the mammal is a human.

11. The method according to claim 3 , wherein the mammal is a human.

12. The method according to claim 4 , wherein the mammal is a human.

13. The method according to claim 5 , wherein the effective amount administered is about 10-500 μg/patient.

Assignments (9)
RELEASE OF SECURITY INTEREST Recorded Dec 16, 2022
From: ATHYRIUM OPPORTUNITIES III ACQUISITION LP
To: SOCIETAL CDMO, INC.
Reel/Frame 062123/0184 →
SECURITY INTEREST Recorded Jun 10, 2020
From: BAUDAX BIO N.A. LLC; BAUDAX BIO LIMITED; BAUDAX BIO, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 052891/0590 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 30, 2020
From: RECRO PHARMA, INC.
To: BAUDAX BIO, INC.
Reel/Frame 051671/0536 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE NAME PREVIOUSLY RECORDED AT REEL: 044166 FRAME: 0008. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST. Recorded Mar 8, 2019
From: RECRO PHARMA, INC.
To: ATHYRIUM OPPORTUNITIES III ACQUISITION LP
Reel/Frame 048540/0415 →
RELEASE OF SECURITY INTEREST Recorded Nov 17, 2017
From: ORBIMED ROYALTY OPPORTUNITIES II, LP
To: RECRO PHARMA, INC.
Reel/Frame 044481/0907 →
SECURITY INTEREST Recorded Nov 17, 2017
From: RECRO PHARMA, INC.
To: ATHYRIUM OPPORTUNITIES III ACQUSITION LP
Reel/Frame 044166/0008 →
SECURITY INTEREST Recorded Apr 14, 2015
From: RECRO PHARMA, INC.
To: ORBIMED ROYALTY OPPORTUNITIES II, LP
Reel/Frame 035403/0197 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 27, 2013
From: HEINO, RIITTA; LEINO, TIINA; LEHTIMAKI, TARJA
To: ORION CORPORATION
Reel/Frame 031300/0565 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 31, 2011
From: ORION CORPORATION
To: RECRO PHARMA, INC.
Reel/Frame 026840/0879 →